

**RECEIVED**  
**CENTRAL FAX CENTER**

001/066


MAY 21 2008

GOODWIN | PROCTER

Goodwin Procter LLP  
 Counselors at Law  
 The New York Times Building  
 620 Eighth Avenue  
 New York, NY 10018-1405  
 T: 212.813.8800  
 F: 212.355.3333

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence, and attachments, if any, are being facsimile transmitted to Group Art Unit 1614 of the USPTO at fax number (571) 272-8300 on May 21, 2008.

  
 Sherise Reovan

May 21, 2008  
 Date

**F A X T R A N S M I T T A L**

If problems with transmittal, call fax department at 212.813.8800.

Date	Total pages
May 21, 2008	66

To	Company	Fax number	Telephone
Commissioner for Patents	U.S. Patent and Trademark Office	(571) 273.8300	(571) 272.1600
From		Fax number	Telephone
Timothy J. Doyle		212.355.3333	212.459.7483


**Message:**

Appl. No. : 10/632,187  
 Applicant : Jürgen Engel, Eckhard Günther, and Herbert Sindermann  
 Filed : July 30, 2003  
 Title : USE OF ALKYLPHOSPHOCHOLINES IN COMBINATION WITH ANTITUMOR MEDICATIONS FOR THE TREATMENT OF BENIGN AND MALIGNANT ONCOSES IN HUMANS AND MAMMALS  
 TC/A.U. : 1614  
 Examiner : Shirley V. Gembeh  
 Docket No. : 103832-477-NP

Submitted herewith are the following items for filing in the above-identified case:

1. This Fax Transmittal (1 page);
2. 477NP Supplemental IDS (2 pages);
3. Information Disclosure Statement By Applicant (1 page);
4. Cited References (61 pages); and
5. Fee Transmittal (1 page).

For a total of 66 pages. The Commissioner is authorized to charge any required fees, or credit any overpayment, to Goodwin Procter LLP Deposit Account No. 06-0923.

  
 Timothy J. Doyle, Reg. No. 58,127

The information contained in this communication is intended only for the personal and confidential use of the designated recipients addressed. This message may be an attorney-client communication from an attorney at the law firm of Goodwin Procter LLP and as such is privileged and confidential. If the reader of this message is not the intended recipient, you are hereby notified that you have received this communication in error, and that any review, dissemination, distribution or copying of this message is strictly prohibited. If you have received this communication in error, please notify us at the telephone number shown above, and return the original message to us by mail. Thank you.

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Appl. No. : 10/632,187  
Applicant : Jürgen Engel et al.  
Filed : July 30, 2003  
Title : Use Of Alkylphosphocholines In Combination With Antitumor  
Medications For The Treatment Of Benign And Malignant  
Oncoses In Humans And Mammals  
Attorney Docket No. : 103832-477-NP

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Sir:

Under the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants bring to the attention of the Examiner the documents listed on the attached Form PTO/SB/08b.

A fee transmittal form accompanies this supplemental Information Disclosure Statement, which authorizes the Commissioner to charge the requisite fee of \$180.00, as set forth in 37 C.F.R. § 1.17(p), for compliance with 37 C.F.R. § 1.97(c). Applicants are not aware of any additional relevant references at this time.


05/22/2008 PCHOMP 00000011 060923 10632187  
01 FC:1006 180.00 DA

Appl. No. 10/632,187  
Supplemental Information Disclosure Statement

It is believed that no additional fees are due, however, if it is determined that additional fees are due, the Commissioner is authorized to charge any additional fees or to credit any overpayment to Goodwin Procter LLP Deposit Account 06-0923.

Respectfully submitted,

Dated: May 21, 2008

  
\_\_\_\_\_  
Timothy Doyle (Reg. No. 58,127)  
GOODWIN PROCTER LLP  
The New York Times Building  
620 Eighth Avenue  
New York, NY 10019-1405  
(212) 459-7483